Also, fluvoxamine (a powerful inhibitor of CYP1A2 in addition to a weak inhibitor of CYP3A4 and CYP2C9) and ciprofloxacin (a solid inhibitor of CYP1A2 along with a reasonable inhibitor of CYP3A4) also are likely to inhibit zolpidem’s metabolic pathways, potentially resulting in a rise in zolpidem exposure. Identify your collection: https://peterd542pfl5.blogunteer.com/profile